文件类型:PDF文档
文件大小:1308K
The present invention relates to a method for post-surgical treatment of breast cancer in women suffering from such cancer, whereby a therapeutically effective amount of an extracellular regulated kinase, (ERK-p), phosphorylation inhibitor is administered to provide for an re-expression of estrogen receptor-α (ER-α) protein and/or restoration of anti-estrogen (SERMS; selective ER modulators, SAMs; selective aromatase Inhibitors and specific estrogen receptor inhibitors as Faslodex) treatment response.